Market Newsdesk

SANTA CLARA, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) — Today at its annual Technology Summit in California, GlobalFoundries (Nasdaq: GFS)(GF) announced the availability of its 22FDX+ with Resistive RAM (RRAM) technology, marking a significant advancement in the company’s portfolio of embedded non-volatile memory (eNVM) solutions. The new RRAM technology, when combined with the high-performance, ultra-low power 22FDX® platform, delivers secure, low-latency, high-density embedded memory for code storage for wireless microcontrollers and AI IoT applications.

Designed with industry-proven OxRAM technology, GF’s embedded RRAM offers cost-effective memory with low power read/write, high endurance and excellent retention. On-chip integration with GF’s enhanced 22FDX platform delivers improved data retention, reliability, security and power efficiency, creating compact and versatile system-on-chip (SoC) solutions for intelligent, connected devices.

RRAM’s high density and scalability are ideal for AI-enabled, IoT devices that rely on high-performance intelligence at the edge, such as sensors, wearables and industrial systems. 22FDX+ RRAM also enables weight storage for neural networks, enabling more effective and complex networks.

“We are pleased to add 22FDX+ RRAM to GF’s growing portfolio of differentiated technologies with the advanced features needed for power-efficient, connected intelligence at the edge,” said Ed Kaste, senior vice president of GF’s ultra-low power CMOS product line. “Our latest solution offers a compelling combination of density, performance and power efficiency, making it well-suited to tackle the challenges of next-generation, AI-enabled and connected devices.”

“GlobalFoundries is an important partner for Nordic Semiconductor as we push the boundaries of ultra-low power wireless solutions for the next generation of connected products and AI-enabled devices,” said Oyvind Strom, EVP Short-Range at Nordic Semiconductor. “We welcome GF’s introduction of embedded RRAM as a significant advancement that enables secure, scalable, and power-efficient edge intelligence. This kind of innovation – delivered through a resilient global supply chain – is essential to meeting growing demands for performance, reliability, and sustainability in connected systems.”

A macro preliminary design kit for 22FDX+ RRAM is available through GF’s self-service GF Connect portal to help jumpstart the design process. Volume production is slated for 2026, driven by several key customer engagements. Future generations of embedded RRAM technology and deployments to other platforms are in development.

About GF

GlobalFoundries (GF) is a leading manufacturer of essential semiconductors the world relies on to live, work and connect. We innovate and partner with customers to deliver more power-efficient, high-performance products for the automotive, smart mobile devices, internet of things, communications infrastructure and other high-growth markets. With our global manufacturing footprint spanning the U.S., Europe, and Asia, GF is a trusted and reliable source for customers around the world. Every day, our talented global team delivers results with an unyielding focus on security, longevity, and sustainability. For more information, visit www.gf.com.

Forward-looking information

This news release may contain forward-looking statements, which involve risks and uncertainties. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. GF undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Media Contact:

Stephanie Gonzalez
[email protected]

New York, August 28, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator and Kyivstar Group Ltd. (Nasdaq: KYIV; KYIVW), a leading telecommunications and digital operator in Ukraine (“Kyivstar”), announced today that Kyivstar will host an investor meeting on Thursday, August 28, 2025, from 10:00 AM to 11:30 AM Eastern Time.

The meeting will provide an update on Kyivstar’s strategic initiatives, financial performance, and market outlook. Members of the senior management team will present key developments from the second quarter 2025 results and engage with investors during a Q&A session.

Event Details:

Date: Thursday, August 28, 2025
Time: 10:00 AM – 11:30 AM Eastern Time
Location: Virtual (https://icrinc.zoom.us/webinar/register/WN_EaNErH0vTP683Bj_bz7e_Q)

Investors and analysts interested in attending the meeting are encouraged to join via the link provided above. Additional information, including access details and presentation materials, will be made available on Kyivstar’s Investor Relations website: https://investors.kyivstar.ua.

About Kyivstar

Kyivstar is a Nasdaq-listed company and Ukraine’s leading digital operator, serving nearly 22.4 million mobile customers and over 1.1 million home internet fixed line customers as of June 30, 2025. Kyivstar and its subsidiaries provide services across a wide range of mobile and fixed line technologies, including 4G, big data, cloud solutions, cybersecurity, digital TV, and more. Together with its parent company VEON, Kyivstar intends to invest USD 1 billion in Ukraine during 2023-2027, through social investments in infrastructure and technological development, charitable donations and strategic acquisitions. operating in Ukraine for more than 27 years, Kyivstar is the first Ukrainian investment opportunity in U.S. stock exchanges. For more information, visit https://investors.kyivstar.ua.

About VEON

VEON is a digital operator that provides connectivity and digital services to nearly 160 million customers. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on Nasdaq. For more information, visit: www.veon.com.

Contact Information

VEON
[email protected]

Kyivstar Group Ltd.
[email protected]
https://investors.kyivstar.ua

LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) —


IMUNON


, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following confirmation from the Nasdaq Hearings Panel. As a result, IMUNON common stock will continue uninterrupted trading on The Nasdaq Capital Market.

“Having regained compliance with Nasdaq’s minimum bid price listing requirement, investors in IMUNON’s stock are assured of efficient liquidity as provided by the exchange. Our ongoing confidence in our listing with the Nasdaq coincides with our recent 15% stock dividend to shareholders of record as of August 7, 2025, reflecting confidence in our clinical pipeline and commitment to rewarding investors,” said Stacy Lindborg, Ph.D., President and CEO of IMUNON. “It also builds on the positive momentum following our unprecedented Phase 2 OVATION 2 trial results for IMNN-001, our DNA-based immunotherapy for the localized treatment of advanced ovarian cancer, a disease that results in 20,000 women newly diagnosed annually in the U.S. alone. We have successfully initiated our Phase 3 OVATION 3 trial in North America, while continuing to advance milestones across our innovative TheraPlas^® technology platform.”

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas^®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine^®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to our ability to regain compliance with Nasdaq’s listing requirements, the potential de-listing of our shares on Nasdaq, risks and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in upcoming investor conferences with associated one-on-one investor meetings.

Citi’s 2025 Biopharma Back to School Conference (Boston, MA)

Date/Time: Wednesday, September 3, 2025, at 9:00 AM ET
Webcast Link: Citi / Candel Fireside Chat

Cantor Global Healthcare Conference (New York, NY)

Date/Time: Thursday, September 4, 2025, at 8:00 AM ET
Webcast Link: Cantor / Candel Fireside Chat

H.C. Wainwright 27th Annual Global Investment Conference (New York, NY)

Date/Time: Friday, September 5, 2025, at 7:00 AM ET
Webcast Link: H.C. Wainwright / Candel Presentation

Live webcasts of the presentations will be available by selecting Events and Presentations under the News & Events tab in the Investors section on www.candeltx.com. A replay of the webcasts will be archived for up to 90 days following the session date.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform.

The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Regenerative Medicine Advanced Therapy Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC and prostate cancer, and both Fast Track and Orphan Drug Designation to CAN-2409 for the treatment of PDAC.

CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; and expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat solid tumors. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact

Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
[email protected]

Media Contact

Ben Shannon
Vice President
ICR Healthcare
[email protected]

CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the upcoming investor conferences detailed below.

2025 Wells Fargo Healthcare Conference

Date: Wednesday, September 3, 2025
Presentation: 2:15 PM ET
Webcast Link

2025 Cantor Global Healthcare Conference

Date: Thursday, September 4, 2025
Presentation: 3:20 PM ET
Webcast Link

H.C. Wainwright 27th Annual Global Investment Conference

Date: Monday, September 8, 2025
Presentation: 9:00am ET
Webcast Link         

Baird Global Conference

Date: Tuesday, September 9, 2025
Presentation: 12:50pm ET
Webcast Link         

The webcasts will be available under the Investors section on the Company’s website, www.catalystpharma.com, and a replay will be available for at least 30 days.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America’s Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst’s website at www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.